Breakthrough in Pancreatic Cancer Treatment!
Pancreatic cancer as one of the lowest cancer survival rates as patients often don’t present with symptoms until the disease has progressed significantly. As such, pancreatic cancers such as Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognoses and patient outcomes. Previous work has shown that three pathways are known targets for therapies, however each pathway presents different hurdles such as the induction of tumour resistance to the treatment.
Last week it was reported that a group in Spain published a study that was conducted in mice, whereby PDAC tumours were grown in mice (north genetically induced and xenografts) and all three of these pathways (RAF1, EGFR, and KRAS) were targeted simultaneously through a combination of selective inhibitors. The trial resulted in complete regression of the tumours, no evidence of tumour resistance and no tumour relapses. The treatment was well-tolerated, with the mice exhibiting no negative side-effects of the course of treatment.
This study was published in December and presents a promising avenue to explore and potential for human trials.
Please read, rate and review the paper here:
